Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Jefferies Continues to See Low Probablity of Sarepta (SRPT) Approval
June 7, 2016 7:50 AM EDTprice target on Jefferies analyst Gena Wang maintained her Underperform rating and $7 PT on Sarepta Therapeutic (NASDAQ: SRPT), saying the dystrophin request is the best-case scenario, but they still see a slim chance of approval.
Wang commented, "We see FDA's request for additional... More
Sarepta (SRPT): Accelerated Approval Seen Pending Dystrophin Data Analysis - Oppenheimer
June 7, 2016 6:49 AM EDTOppenheimer analyst, Christopher Marai, reiterated his Outperform rating after Sarepta Therapeutic (NASDAQ: SRPT) announced the FDA has requested dystrophin data (n=13) from ongoing PROMOVI confirmatory trial of eteplirsen, prior to making an approval decision. SRPT indicated to us biopsies have been completed but... More
Amid Dystrophin Data Request, Uncertainty Remains in Sarepta (SRPT) - Leerink
June 7, 2016 6:16 AM EDTLeerink affirms Sarepta (Nasdaq: SRPT) at Underperform with a price target of $5 after the company announced that the U.S. Food and Drug... More
Sarepta Therapeutics (SRPT) Surges as FDA Requests Dystrophin Data for eteplirsen NDA
June 6, 2016 5:45 PM EDTSarepta Therapeutics (NASDAQ: SRPT) is gaining sharply after the company announced that the FDA has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing... More
